However, despite over 30 years of clinical trials investigating PKC inhibitors as anti-cancer agents, PKC inhibitors have failed to show tumor-suppressive effects and, in some cases, have worsened symptoms [12]. This evidence concerns the gene PRRT2 and cancer.